Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma. - Trial NCT05811793
Access comprehensive clinical trial information for NCT05811793 through Pure Global AI's free database. This phase not specified trial is sponsored by Second Affiliated Hospital of Nanchang University and is currently Not yet recruiting. The study focuses on Glioblastoma. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Second Affiliated Hospital of Nanchang University
Timeline & Enrollment
N/A
Apr 15, 2023
Dec 30, 2025
Primary Outcome
Progression-Free Survival
Summary
To investigate the efficacy, safety and tolerability of superselective cerebral arterial
 infusion of Bevacizumab combined with intrathecal injection of Tislelizumab in the treatment
 of recurrent glioblastoma
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05811793
Non-Device Trial